Search clinical trials for: Memantine Hydrochloride MR Prototype Capsule Formulation C

Total 32 results

Lyndra Inc.

Terminated

Study Determining Gastric-Retentive and Modified Release Properties of Prototype Capsules in Healthy Subjects

Healthy | Gastric Retention

United Kingdom
Medicines for Malaria Venture
Quotient Clinical

Completed

Bioavailability Study of Oral OZ439 Prototype Formulations Administered With Piperaquine Phosphate (PQP)

Malaria

United Kingdom
Lyndra Inc.

Completed

Study to Evaluate Safety/Duration in Stomach of Extended Release Capsules in Healthy Adults

Healthy | Gastric Retention

Australia
H. Lundbeck A/S

Completed

A Study Investigating Tablet Formulations of Lu AF11167 in Healthy Subjects

Healthy

United Kingdom
Forest Laboratories

Completed

Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine

Autistic Disorder | Autism | Autism Spectrum Disorders | Asperger Syndrome | Asperger's Disorder | Pervasive Developmental Disorder - Not Otherwise Specified (PDD-NOS)

United States, Belgium, Colombia, Estonia, France, Hungary, Iceland, Italy, Korea, Republic of, New Zealand, Poland, Serbia, South Africa, Spain, Ukraine
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety of BILR 355 in Healthy Male Volunteers

Healthy
Sucampo Pharma Americas, LLC
Takeda

Completed

Comparative Pharmacokinetics and Food-Effect Bioavailability of Lubiprostone Sprinkle in Healthy Volunteers

Healthy Volunteers

United States
Children's Oncology Group

Recruiting

A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for Primary Central Nervous System Tumors

Central Nervous System Carcinoma

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma | Hematopoietic and Lymphatic System Neoplasm

United States
Torrent Pharmaceuticals Limited

Completed

Bioequivalence Study of Torrent Pharmaceutical Limited's Venlafaxine Hydrochloride ER Capsules Under Fed Conditions

Healthy
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).

Advanced Non-squamous Non-small Cell Lung Cancer

China
Monash Medical Centre
Monash University

Recruiting

FASST - Fetal Alcohol Spectrum Stimulant Trial (FASST)

Fetal Alcohol Spectrum Disorders

Australia
Maastricht University Medical Center
VitaK

Unknown

The Effects of Vitamin K2 Supplementation on the Progression of Coronary Artery Calcification (VitaK-CAC)

Coronary Artery Disease

Netherlands
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of Copanlisib to Eribulin for the Treatment of Advanced-Stage Triple Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Unresectable Triple-Negative Breast Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Withdrawn

Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent Ovarian Endometrioid Adenocarcinoma | Recurrent Platinum-Resistant Fallopian Tube Carcinoma | Recurrent Platinum-Resistant Primary... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors

Malignant Solid Neoplasm

United States
University of Rochester

Completed

Impact of Metformin in Teens With Polycystic Ovary Syndrome (PCOS) on Oral Contraceptive Therapy

Polycystic Ovary Syndrome

United States
University Hospital of Split

Enrolling by invitation

The Efficacy of Tamsulosin and Tadalafil Compared to Placebo in the Treatment and Prevention of Urinary Disorders After Transperineal Prostate Biopsy

Quality of Life | Pain | Lower Urinary Tract Symptoms | Voiding Disorders

Croatia
National Cancer Institute (NCI)

Completed

Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Hepatocellular Carcinoma | Unresectable Hepatocellular Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Osel, Inc.
National Cancer Institute (NCI); City of Hope Medical Center; Miyarisan Pharmaceuticals...

Recruiting

CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer

Metastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Advanced Sarcomatoid Renal...

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Terminated

Individualized Drug Treatment for Treating Patients With Pancreatic Cancer

Pancreatic Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes (The INSPIRE Study)

Stage III Bladder Cancer AJCC v8 | Bladder Urothelial Carcinoma

United States
University of Washington
National Cancer Institute (NCI)

Completed

Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery

HER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast Cancer

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Individualized Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Invasive Breast Carcinoma | Metastatic Triple-Negative Breast Carcinoma

United States
National Cancer Institute (NCI)

Suspended

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Acute Myeloid Leukemia

United States, Canada, Puerto Rico, Australia
Flemming Forsberg
National Cancer Institute (NCI)

Recruiting

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Unresectable...

United States, Norway
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Recurrent Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Refractory Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Lymphoma | Clonal Cytopenia of Undetermined Significance | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

United States
Hannover Medical School

Terminated

Pharmacovigilance in Gerontopsychiatric Patients (GAP)

Depression | Schizophrenia | Anxiety Disorders | Dementia | Psychosomatic Disorders

Germany
National Cancer Institute (NCI)

Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Glioma | Hematopoietic and Lymphoid Cell Neoplasm | Melanoma | Lymphoma | Multiple Myeloma | Recurrent Ovarian Carcinoma | Breast Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Skin Carcinoma | Gastric Carcinoma | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory... and other conditions

United States, Puerto Rico, Guam
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

B Acute Lymphoblastic Leukemia | Central Nervous System Leukemia | Testicular Leukemia | B Lymphoblastic Lymphoma | Mixed Phenotype Acute Leukemia

United States, Canada, Australia, Puerto Rico, New Zealand

Search clinical trials for: Memantine Hydrochloride MR Prototype Capsule Formulation C

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations